Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.51 |
| ▸ | TP53 | P04637 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.49 |
| ▸ | RELA | Q04206 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.47 |
| ▸ | NAMPT | P43490 | 2/20 | 0.47 |
| ▸ | F10 | P00742 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3441352 | 0.86 | SMN1; SMN2 (0.46) | SMN1; SMN2TP53HPGDNPC1RAB9A | |
| SCHEMBL3573442 | 0.82 | GPR119 (0.50) | SMN1; SMN2NPC1RAB9AMAPTGPR119 | |
| SCHEMBL25666815 | 0.82 | F10 (0.41) | TP53MAPTKMT2AGPR119F10 | |
| SCHEMBL30817330 | 0.81 | GPR119 (0.48) | SMN1; SMN2TP53HPGDMAPTKMT2A | |
| SCHEMBL10118830 | 0.81 | MCHR1 (0.49) | SMN1; SMN2MAPTGPR119NAMPT | |
| SCHEMBL993933 | 0.79 | GAA (0.64) | SMN1; SMN2NPC1RAB9AMAPTKMT2A | |
| SCHEMBL8346062 | 0.79 | PRKDC (0.63) | SMN1; SMN2TP53NPC1RAB9AMAPT | |
| SCHEMBL30817405 | 0.78 | MAPT (0.50) | SMN1; SMN2TP53HPGDNPC1RAB9A | |
| SCHEMBL6503210 | 0.78 | MAPT (0.50) | SMN1; SMN2TP53HPGDNPC1RAB9A | |
| SCHEMBL21135512 | 0.78 | NAMPT (0.49) | SMN1; SMN2TP53HPGDNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167118-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INIDBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167118-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INIDBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BTK, CBL, SYK | SMN1; SMN2 4065/4885TP53 2615/4885HPGD 4296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.